Sanofi
SNYNFDrugs in Pipeline
106
Phase 3 Programs
63
Upcoming Catalysts
1
Next Catalyst
Dec 23, 2026
42wMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
Teriflunomide
Multiple Sclerosis
Cetylpyridinium chloride
Healthy
Lipid-Modifying Therapy (LMT)
Hypercholesterolemia
SR58611A
Depressive Disorder
Lunsekimig
Chronic Obstructive Pulmonary Disease
telithromycin (HMR3647)
Infections
Clopidogrel (SR25990)
Acute Coronary Syndromes
Vandetanib
Thyroid Neoplasms
Lactic Acid
Hygiene
gemcitabine
Urinary Bladder Neoplasms
Larotaxel (XRP9881)
Pancreatic Neoplasms
Saredutant
Depressive Disorder
rilzabrutinib
Immune Thrombocytopenia
SR121463B
Inappropriate ADH Syndrome
Insulin glulisine
Diabetes Mellitus, Type 1
Rimonabant
Diabetes Mellitus, Type 2
sarilumab SAR153191 (REGN88)
Rheumatoid Arthritis
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Meningococcal Infection (Healthy Volunteers)
Alemtuzumab
Multiple Sclerosis, Relapsing-Remitting
lactoserum
Hygiene
Insulin glargine
Diabetes Mellitus, Type 1
Lispro
Diabetes Mellitus
Thyrogen + Radioiodine (131I)
Thyroid Neoplasms
efanesoctocog alfa (BIVV001)
Factor VIII Deficiency
alfuzosin (SL770499)
Urinary Bladder Neurogenic
Olipudase alfa
Sphingomyelin Lipidosis
Enoxaparin sodium
Percutaneous Coronary Intervention
ZD6474 (vandetanib)
Non-Small-Cell Lung Carcinoma
MenACYW conjugate vaccine
Meningococcal Immunisation
Alirocumab
Hypercholesterolemia
Lipid Modifying Therapy (LMT)
Hypercholesterolaemia
Aflibercept
Colorectal Cancer Metastatic
ezetimibe
Hypercholesterolemia
Influenza virus vaccine (split virion, inactivated)
Influenza
Caplacizumab
Acquired Thrombotic Thrombocytopenic Purpura
ALIROCUMAB SAR236553 (REGN727)
Hypercholesterolemia
Glimepiride
Diabetes Mellitus, Non-Insulin-Dependent
Sitagliptin
Type 2 Diabetes Mellitus
Insulin glargine/Lixisenatide (HOE901/AVE0010)
Type 2 Diabetes Mellitus
Docetaxel
Lung Neoplasms
Ciclesonide (XRP1526)
Asthma
Metformin
Diabetes Mellitus, Type 2
Irbesartan
Atrial Fibrillation
Dermacyd PH_DETINLYN (Lactic Acid)
Hygiene
Lixisenatide (AVE0010)
Type 2 Diabetes Mellitus
Fexofenadine
Asthma
LACTIC ACID(ND)
Hygiene
Dupilumab
Chronic Spontaneous Urticaria
Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Diphtheria
Insuline glulisine
Diabetes Mellitus, Type 1
leflunomide
Arthritis, Rheumatoid
Sarilumab
Rheumatoid Arthritis
Myozyme
Glycogen Storage Disease Type II
Rimonabant (SR141716)
Obesity
amibegron (SR58611A)
Major Depressive Disorders
Dermacyd PH_DETINBACK (Lactic Acid)
Hygiene
Semuloparin sodium
Venous Thromboembolism
Alfuzosin
Prostatic Hyperplasia
Lactic acid (Dermacid)
Hygiene
Itepekimab SAR440340
Chronic Obstructive Pulmonary Disease
Insulin glulisine QD
Type 2 Diabetes
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)
Meningococcal Immunisation (Healthy Volunteers)
Eliglustat tartrate
Gaucher Disease, Type 1
Clopidogrel
Ischemia
Split, Inactivated, Trivalent Influenza Vaccine
Orthomyxoviridae Infection
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
Systemic Sclerosis
G-CSF Plus Plerixafor
Lymphoma, Non-Hodgkin
frexalimab
Focal Segmental Glomerulosclerosis
XL147 (SAR245408)
Breast Cancer
Fluticasone/Salmeterol combination therapy
Asthma
SAR443122
Cutaneous Lupus Erythematosus
Alglucosidase alfa
Glycogen Storage Disease Type II
Isatuximab
Relapsed/Refractory Multiple Myeloma
Inactivated, split-virion influenza vaccine
Influenza
Oxaliplatin
Stomach Neoplasms
Belumosudil
Chronic Graft Versus Host Disease
SAR441566
Psoriasis
Iniparib
Breast Cancer, Metastatic
Fludarabine Phosphate (Fludara)
Non Hodgkin Lymphoma
Amlitelimab
Asthma
ATN-103
Active Rheumatoid Arthritis
CYD Dengue Vaccine
Dengue
clofarabine
Acute Myelogenous Leukemia
SAR442970
Ulcerative Colitis
Methotrexate
Rheumatoid Arthritis
ALX-0061
Rheumatoid Arthritis
RISEDRONATE
OSTEOPOROSIS, POSTMENOPAUSAL
Atorvastatin
Hypercholesterolemia
SAR156597
Systemic Sclerosis
SR57667B
Parkinson Disease
Fabrazyme (agalsidase beta)
Fabry Disease
rasburicase (SR29142)
Nutritional and Metabolic Diseases
RSVt Vaccine
Respiratory Syncytial Virus Infection
Tolebrutinib
Relapsing Multiple Sclerosis
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Neoplasms
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
Meningitis
Acne mRNA vaccine
Acne
eplivanserin (SR46349)
Fibromyalgia
ombrabulin (AVE8062)
Non-small Cell Lung Cancer
gemcitabine/carboplatin
Breast Cancer
tolevamer potassium-sodium (GT267-004)
Pseudomembranous Colitis
A/H5N1 inactivated, split-virion influenza virus
Influenza
ILX651
Hormone-refractory Prostate Cancer
Avalglucosidase Alfa
Glycogen Storage Disease Type II Pompe Disease
ZD6474, Vandetanib
Biliary Tract Cancer
satavaptan (SR121463B)
Ascites
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Teriflunomide | Phase 3 | Multiple Sclerosis | - | - |
Cetylpyridinium chloride | Phase 3 | Healthy | - | - |
Lipid-Modifying Therapy (LMT) | Phase 3 | Hypercholesterolemia | - | - |
SR58611A | Phase 3 | Depressive Disorder | - | - |
Lunsekimig | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
telithromycin (HMR3647) | Phase 3 | Infections | - | - |
Clopidogrel (SR25990) | Phase 3 | Acute Coronary Syndromes | - | - |
Vandetanib | Phase 3 | Thyroid Neoplasms | - | - |
Lactic Acid | Phase 3 | Hygiene | - | - |
gemcitabine | Phase 3 | Urinary Bladder Neoplasms | - | - |
Larotaxel (XRP9881) | Phase 3 | Pancreatic Neoplasms | - | - |
Saredutant | Phase 3 | Depressive Disorder | - | - |
rilzabrutinib | Phase 3 | Immune Thrombocytopenia | - | - |
SR121463B | Phase 3 | Inappropriate ADH Syndrome | - | - |
Insulin glulisine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Rimonabant | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
sarilumab SAR153191 (REGN88) | Phase 3 | Rheumatoid Arthritis | - | - |
Meningococcal Polysaccharide (serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine | Phase 3 | Meningococcal Infection (Healthy Volunteers) | - | - |
Alemtuzumab | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
lactoserum | Phase 3 | Hygiene | - | - |
Insulin glargine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Lispro | Phase 3 | Diabetes Mellitus | - | - |
Thyrogen + Radioiodine (131I) | Phase 3 | Thyroid Neoplasms | - | - |
efanesoctocog alfa (BIVV001) | Phase 3 | Factor VIII Deficiency | - | - |
alfuzosin (SL770499) | Phase 3 | Urinary Bladder Neurogenic | - | - |
Olipudase alfa | Phase 3 | Sphingomyelin Lipidosis | - | - |
Enoxaparin sodium | Phase 3 | Percutaneous Coronary Intervention | - | - |
ZD6474 (vandetanib) | Phase 3 | Non-Small-Cell Lung Carcinoma | - | - |
MenACYW conjugate vaccine | Phase 3 | Meningococcal Immunisation | - | - |
Alirocumab | Phase 3 | Hypercholesterolemia | - | - |
Lipid Modifying Therapy (LMT) | Phase 3 | Hypercholesterolaemia | - | - |
Aflibercept | Phase 3 | Colorectal Cancer Metastatic | - | - |
ezetimibe | Phase 3 | Hypercholesterolemia | - | - |
Influenza virus vaccine (split virion, inactivated) | Phase 3 | Influenza | - | - |
Caplacizumab | Phase 3 | Acquired Thrombotic Thrombocytopenic Purpura | - | - |
ALIROCUMAB SAR236553 (REGN727) | Phase 3 | Hypercholesterolemia | - | - |
Glimepiride | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
Sitagliptin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Insulin glargine/Lixisenatide (HOE901/AVE0010) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Docetaxel | Phase 3 | Lung Neoplasms | - | - |
Ciclesonide (XRP1526) | Phase 3 | Asthma | - | - |
Metformin | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
Dermacyd PH_DETINLYN (Lactic Acid) | Phase 3 | Hygiene | - | - |
Lixisenatide (AVE0010) | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Fexofenadine | Phase 3 | Asthma | - | - |
LACTIC ACID(ND) | Phase 3 | Hygiene | - | - |
Dupilumab | Phase 3 | Chronic Spontaneous Urticaria | - | - |
Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib | Phase 3 | Diphtheria | - | - |
Insuline glulisine | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
leflunomide | Phase 3 | Arthritis, Rheumatoid | - | - |
Sarilumab | Phase 3 | Rheumatoid Arthritis | - | - |
Myozyme | Phase 3 | Glycogen Storage Disease Type II | - | - |
Rimonabant (SR141716) | Phase 3 | Obesity | - | - |
amibegron (SR58611A) | Phase 3 | Major Depressive Disorders | - | - |
Dermacyd PH_DETINBACK (Lactic Acid) | Phase 3 | Hygiene | - | - |
Semuloparin sodium | Phase 3 | Venous Thromboembolism | - | - |
Alfuzosin | Phase 3 | Prostatic Hyperplasia | - | - |
Lactic acid (Dermacid) | Phase 3 | Hygiene | - | - |
Itepekimab SAR440340 | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Insulin glulisine QD | Phase 3 | Type 2 Diabetes | - | - |
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine) | Phase 3 | Meningococcal Immunisation (Healthy Volunteers) | - | - |
Eliglustat tartrate | Phase 3 | Gaucher Disease, Type 1 | - | - |
Clopidogrel | Phase 2 | Ischemia | - | - |
Split, Inactivated, Trivalent Influenza Vaccine | Phase 2 | Orthomyxoviridae Infection | - | - |
Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody | Phase 2 | Systemic Sclerosis | - | - |
G-CSF Plus Plerixafor | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
frexalimab | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |
XL147 (SAR245408) | Phase 2 | Breast Cancer | - | - |
Fluticasone/Salmeterol combination therapy | Phase 2 | Asthma | - | - |
SAR443122 | Phase 2 | Cutaneous Lupus Erythematosus | - | - |
Alglucosidase alfa | Phase 2 | Glycogen Storage Disease Type II | - | - |
Isatuximab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Inactivated, split-virion influenza vaccine | Phase 2 | Influenza | - | - |
Oxaliplatin | Phase 2 | Stomach Neoplasms | - | - |
Belumosudil | Phase 2 | Chronic Graft Versus Host Disease | - | - |
SAR441566 | Phase 2 | Psoriasis | - | - |
Iniparib | Phase 2 | Breast Cancer, Metastatic | - | - |
Fludarabine Phosphate (Fludara) | Phase 2 | Non Hodgkin Lymphoma | - | - |
Amlitelimab | Phase 2 | Asthma | - | - |
ATN-103 | Phase 2 | Active Rheumatoid Arthritis | - | - |
CYD Dengue Vaccine | Phase 2 | Dengue | - | - |
clofarabine | Phase 2 | Acute Myelogenous Leukemia | - | - |
SAR442970 | Phase 2 | Ulcerative Colitis | - | - |
Methotrexate | Phase 2 | Rheumatoid Arthritis | - | - |
ALX-0061 | Phase 2 | Rheumatoid Arthritis | - | - |
RISEDRONATE | Phase 2 | OSTEOPOROSIS, POSTMENOPAUSAL | - | - |
Atorvastatin | Phase 2 | Hypercholesterolemia | - | - |
SAR156597 | Phase 2 | Systemic Sclerosis | - | - |
SR57667B | Phase 2 | Parkinson Disease | - | - |
Fabrazyme (agalsidase beta) | Phase 2 | Fabry Disease | - | - |
rasburicase (SR29142) | Phase 2 | Nutritional and Metabolic Diseases | - | - |
RSVt Vaccine | Phase 2 | Respiratory Syncytial Virus Infection | - | - |
Tolebrutinib | Phase 2 | Relapsing Multiple Sclerosis | - | - |
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Phase 2 | Neoplasms | - | - |
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine | Phase 2 | Meningitis | - | - |
Acne mRNA vaccine | Phase 2 | Acne | - | - |
eplivanserin (SR46349) | Phase 2 | Fibromyalgia | - | - |
ombrabulin (AVE8062) | Phase 2 | Non-small Cell Lung Cancer | - | - |
gemcitabine/carboplatin | Phase 2 | Breast Cancer | - | - |
tolevamer potassium-sodium (GT267-004) | Phase 2 | Pseudomembranous Colitis | - | - |
A/H5N1 inactivated, split-virion influenza virus | Phase 2 | Influenza | - | - |
ILX651 | Phase 2 | Hormone-refractory Prostate Cancer | - | - |
Avalglucosidase Alfa | Phase 2 | Glycogen Storage Disease Type II Pompe Disease | - | - |
ZD6474, Vandetanib | Phase 2 | Biliary Tract Cancer | - | - |
satavaptan (SR121463B) | Phase 2 | Ascites | - | - |